Seven Years of Culture Collection of Neisseria gonorrhoeae: Antimicrobial Resistance and Molecular Epidemiology

The emergence of Neisseria gonorrhoeae isolates displaying resistance to antimicrobials, in particular to ceftriaxone monotherapy or ceftriaxone plus azithromycin, represents a global public health concern. This study aimed to analyze the trend of antimicrobial resistance in a 7-year isolate collection retrospective analysis in Italy. Molecular typing on a subsample of gonococci was also included. A total of 1,810 culture-positive gonorrhea cases, collected from 2013 to 2019, were investigated by antimicrobial susceptibility, using gradient diffusion method, and by the N. gonorrhoeae multiantigen sequence typing (NG-MAST). The majority of infections occurred among men with urogenital infections and 57.9% of male patients were men who have sex with men. Overall, the cefixime resistance remained stable during the time. An increase of azithromycin resistance was observed until 2018 (26.5%) with a slight decrease in the last year. In 2019, gonococci showing azithromycin minimum inhibitory concentration above the EUCAST epidemiological cutoff value (ECOFF) accounted for 9.9%. Ciprofloxacin resistance and penicillinase-producing N. gonorrhoeae (PPNG) percentages increased reaching 79.1% and 18.7% in 2019, respectively. The most common sequence types identified were 5,441, 1,407, 6,360, and 5,624. The predominant genogroup (G) was the 1,407; moreover, a new genogroup G13070 was also detected. A variation in the antimicrobial resistance rates and high genetic variability were observed in this study. The main phenotypic and genotypic characteristics of N. gonorrhoeae isolates were described to monitor the spread of drug-resistant gonorrhea.

[1]  S. Lai,et al.  Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020 , 2021, Annals of Emergency Medicine.

[2]  Elizabeth A Torrone,et al.  Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[3]  T. Pumarola,et al.  Antimicrobial susceptibility of Neisseria gonorrhoeae in Barcelona during a five-year period, 2013 to 2017 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[4]  C. Giagulli,et al.  Management of a Case of Peritonitis Due to Neisseria gonorrhoeae Infection Following Pelvic Inflammatory Disease (PID) , 2020, Antibiotics.

[5]  Li-hua Hu,et al.  Gonococcal urethritis caused by a multidrug resistant Neisseria gonorrhoeae strain with high-level resistance to spectinomycin in China , 2020, Emerging microbes & infections.

[6]  A. Anselmo,et al.  Genomic Characterization of Gonococci from Different Anatomic Sites, Italy, 2007-2014. , 2019, Microbial drug resistance.

[7]  M. Unemo,et al.  GONORRHOEA , 2019, Nature Reviews Disease Primers.

[8]  J. del Romero,et al.  Epidemiology, molecular characterisation and antimicrobial susceptibility of Neisseria gonorrhoeae isolates in Madrid, Spain, in 2016 , 2019, Epidemiology and Infection.

[9]  I. Martin,et al.  World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts. , 2019, Sexual health.

[10]  Louise J Jackson,et al.  Gentamicin as an alternative to ceftriaxone in the treatment of gonorrhoea: the G-TOG non-inferiority RCT. , 2019, Health technology assessment.

[11]  Keith A Jolley,et al.  Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications , 2018, Wellcome open research.

[12]  M. Unemo,et al.  Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018 , 2018, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[13]  Raquel Abad,et al.  Public health surveillance of multidrug-resistant clones of Neisseria gonorrhoeae in Europe: a genomic survey , 2018, The Lancet. Infectious diseases.

[14]  S. Harris,et al.  Molecular typing of Neisseria gonorrhoeae – a study of 2013 isolates , 2018 .

[15]  A. Mencacci,et al.  Time trend analysis (2009-2016) of antimicrobial susceptibility in Neisseria gonorrhoeae isolated in Italy following the introduction of the combined antimicrobial therapy , 2017, PloS one.

[16]  L. Sánchez-Busó,et al.  The novel 2016 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization. , 2016, The Journal of antimicrobial chemotherapy.

[17]  R. Ignatius,et al.  Antimicrobial resistance of Neisseria gonorrhoeae isolates in south-west Germany, 2004 to 2015: increasing minimal inhibitory concentrations of tetracycline but no resistance to third-generation cephalosporins , 2016, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[18]  M. Unemo,et al.  Failure of Dual Antimicrobial Therapy in Treatment of Gonorrhea. , 2016, The New England journal of medicine.

[19]  Marleen Temmerman,et al.  Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting , 2015, PloS one.

[20]  A. Mencacci,et al.  Changing Antimicrobial Resistance Profiles among Neisseria gonorrhoeae Isolates in Italy, 2003 to 2012 , 2014, Antimicrobial Agents and Chemotherapy.

[21]  M. Unemo,et al.  Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future , 2014, Clinical Microbiology Reviews.

[22]  R. Evans.  European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[23]  M. Unemo,et al.  The European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP)—a sentinel approach in the European Union (EU)/European Economic Area (EEA) , 2013, Sexually Transmitted Infections.

[24]  M. Unemo,et al.  2012 European guideline on the diagnosis and treatment of gonorrhoea in adults , 2013, International journal of STD & AIDS.

[25]  M. Unemo,et al.  High-Level Cefixime- and Ceftriaxone-Resistant Neisseria gonorrhoeae in France: Novel penA Mosaic Allele in a Successful International Clone Causes Treatment Failure , 2011, Antimicrobial Agents and Chemotherapy.

[26]  M. Unemo,et al.  Review and International Recommendation of Methods for Typing Neisseria gonorrhoeae Isolates and Their Implications for Improved Knowledge of Gonococcal Epidemiology, Treatment, and Biology , 2011, Clinical Microbiology Reviews.

[27]  K. Sankar,et al.  Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[28]  G. Cornaglia,et al.  [Antibacterial activity and pharmacological features of fluoroquinolones and considerations on their use in a nosocomial setting]. , 2007, Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive.

[29]  Kevin A Fenton,et al.  Rapid sequence-based identification of gonococcal transmission clusters in a large metropolitan area. , 2004, The Journal of infectious diseases.